Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

Asuragen announces data from microRNA biomarker study on pancreatic cancer

Asuragen, Inc. announced today that data from a collaborative study with Johns Hopkins regarding microRNA biomarkers for use on pancreatic cyst fluid specimens was presented at the American Pancreatic Association Annual Meeting being held November 2-5, 2011 in Chicago.

4 Nov 2011

Riverview to participate in Atlantic C-PORT-E Elective Angioplasty trial

In May 2009, Riverview Medical Center became part of a research study sponsored by Johns Hopkins University called the Atlantic C-PORT-E Elective Angioplasty trial. Riverview was selected to participate in this research study for its high level of experience and outstanding cardiovascular services.

4 Nov 2011

AHA/ASA honors UH Case Medical Center with Get With The Guidelines-Stroke award

For the third consecutive year, University Hospitals (UH) Case Medical Center has received the American Heart Association/American Stroke Association's Get With The Guidelines--Stroke Gold Plus Quality Achievement Award.

4 Nov 2011

Moderate alcohol consumption during adult life, drinking patterns and breast cancer risk

A well-done analysis by Chen WY et al, published in JAMA assesses the association of moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. The authors use prospectively collected data from the 105,986 women enrolled in the Nurses' Health Study followed up from 1980 until 2008 with an early adult alcohol assessment and 8 follow ups.

4 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Study: NPs can decrease unnecessary ED visits

Adding a nurse practitioner (NP) to a busy hospital staff can decrease unnecessary emergency department (ED) visits, according to a study published in the latest issue of Surgery by researchers at Loyola University Health System.

4 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

EAU, ESTRO and ESMO to host European conference on urological cancers

The 3rd European Multidisciplinary Meeting on Urological Cancers will kick off this Friday, bringing together representatives of three adjacent fields involved in the management of prostate, bladder, kidney, testicular and penile cancer.

3 Nov 2011

Increasing TR2/TR4 expression can lead to higher fetal hemoglobin levels in sickle cell patients

A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.

3 Nov 2011

Benefits of combined therapy for men with high-risk prostate cancer

Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease, shows clinical research led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network.

3 Nov 2011

DexCom signs research and development agreement with Roche

Roche Diagnostics U.S., with its business unit Roche Diabetes Care, a leader in blood glucose monitoring and insulin delivery systems, and DexCom, Inc., a leader in continuous glucose monitoring systems, announced today that they have signed a research and development agreement.

From Roche Sequencing and Life Science 3 Nov 2011

FDA approves Endo Pharmaceuticals' Felodipine Extended-release Tablets

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg.

3 Nov 2011

Celldex third quarter net loss increases to $11.8 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2011. Celldex reported a net loss of $11.8 million, or $0.27 per share, for the third quarter of 2011 compared to a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010.

2 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011